GLENMARK PHARMACEUTICALS
Back to Balance Sheet
|
GLENMARK PHARMACEUTICALS Last 5 Year Total Non-Current Liabilities History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Total Non-Current Liabilities | ₹-357 Cr | ₹2,621 Cr | ₹1,270 Cr | ₹2,804 Cr | ₹3,033 Cr |
What is the latest Total Non-Current Liabilities ratio of GLENMARK PHARMACEUTICALS ?
Year | Total Non-Current Liabilities |
---|---|
Mar2024 | ₹-357 Cr |
Mar2023 | ₹2,621 Cr |
Mar2022 | ₹1,270 Cr |
Mar2021 | ₹2,804 Cr |
Mar2020 | ₹3,033 Cr |
How is Total Non-Current Liabilities of GLENMARK PHARMACEUTICALS Trending?
Years | Total Non-Current Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹-357 Cr | Negative | |
Mar2023 | ₹2,621 Cr | 106.48 | |
Mar2022 | ₹1,270 Cr | -54.72 | |
Mar2021 | ₹2,804 Cr | -7.56 | |
Mar2020 | ₹3,033 Cr | - |
Compare Total Non-Current Liabilities of peers of GLENMARK PHARMACEUTICALS
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
GLENMARK PHARMACEUTICALS | ₹56,959.2 Cr | -2.7% | 5.9% | 41.3% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹380,702.0 Cr | -3.3% | -4.6% | -7.9% | Stock Analytics | |
DIVIS LABORATORIES | ₹156,908.0 Cr | -9% | -13.6% | 24% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹120,896.0 Cr | -1.1% | 7% | 8.2% | Stock Analytics | |
CIPLA | ₹119,988.0 Cr | -2% | 0.6% | -4% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹101,122.0 Cr | -1.1% | -3.8% | -13.3% | Stock Analytics |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
GLENMARK PHARMACEUTICALS | -2.7% |
5.9% |
41.3% |
SENSEX | -0.9% |
-4.4% |
1.6% |
You may also like the below Video Courses